References
- Umezawa H, Umezawa S, Tsuchia T, Okazaki Y. 3’4’ Dideoxykanamycin B active against kanamycin resistant Escherichia coli and Pseudomonas aeruginosa. J Antibiot. 1971; 40: 485–7.
- Goto M, Sugiyama M, Ishizaki T. Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous intramuscular administration to human volunteers. Antimicrob Agents Chemother. 1980; 18: 372–6.
- Campillo J A, Lanao JM, Dominguez-Gil A, Fubio I . Martin A. Disposition of Dibekacin in patients undergoing haemodialysis. Eur J Clin Pharmacol. 1980; 18: 347–50.
- Fu KP, Neu NC. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother. 1978; 13: 930–8.
- Pancoast SJ, Jahre JA, Neu HC. Mezlocillin in the therapy of serious infections. Am J Med. 1979; 67: 747–52.
- Aronoff OR, Sloan RS, Luft FC, Nelson RL, Max well DR. Kleit SA. Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther. 1980; 28 523–8.
- Graybill JR. Drutz DJ, Murphy AL. Ketoconazole: A major innovation for treatment of fungal disease. Ann Int Med. 1980; 93: 921–3.
- First International Symposium on Ketoconazole. Rev Infect Dis. 1980; 2: 519–699.
- Petersen EA, Ailing DW, Kirpatrick CH. Treatment of chronic mucocutaneous candidasis with Ketoconazole, Ann Int Med. 1980; 93: 791–5.
- Nelson RL, Allen LA, Creaven PJ. Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther. 1976; 19; 365–70.
- Schnitker J. Brock N, Burkert H, Fichtner E. Evaluation of a cooperative clinical study of the cytostatic agent iphospliamide. Arnzneim. Forsch/Drug Res. 1976; 26: 1783–93.
- Allen LM, Creaven PJ. Comparison of the human pharmacokinetics of VM-26 and VP 16, two antineoplastic epipoodophyllotoxin glycopyranoside derivatives. Europ J Cancer 1975; II: 697–707.
- Hansen HH, Rrth M. Lung cancer. In: Cancer Chemotherapy 1979, HM Pinedo ed. Amsterdam and Oxford: Excerpta Medica 1979; 267–91.
- Rozenczweig M, Von Hoff DD, Menney JE, Muggia I’M. VM-26 and VP 16–213: a comparative analysis. Cancer. 1977; 40: 334–42.
- Jun HW, Hayes SL, Vallner JJ, Honigberg 1L, Rojos AH, Stewart JT. Plasma level profiles and clinical response of penbutolol after three different single oral doses in man. J Clin Pharmacol. 1979; 19: 415–23.
- Giudicelli JF, Richer C, Chauvin M, Idrissi N, Berdeaux Z. Comparative β adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Brit J Clin Pharmacol. 1977; 4: 135 40.
- De Plaen JF, Vander Elst E, van Ypersele C. Penbu tolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements. Brit J Clin Pharmacol. 1981; 12: 215–21.
- Hell RC, Brogden RN, Speight TM, Avery GS. Penbutolol: A preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1981; 22: 1–25.